Ceapro Inc V.CZO

Copilot: potential benefits of avenanthramide

[prophetoffactz]

CZO's pill has shown no adverse events at a single dose of 30mg per day and 60mg per day. 120mg has been administered with results in the first week of March. Here's what Copilot says about the potential health benefits of avenanthramide at the various dose levels potentially in CZO's clinical trial. You can see where CZO may be establishing new ground.

-------------

Avenanthramides, natural compounds found in oats, have garnered attention for their potential health benefits. Let’s explore their effects at different dose levels:

1. Single Doses:

   • 30 mg per day: Avenanthramides have strong antioxidant activity both in vitro and in vivo1.
   • 60 mg per day: At this dose, they may contribute to anti-inflammatory effects1.
   • 120 mg per day: Avenanthramides could exhibit antiproliferative properties1.
   • 240 mg per day: This dose might provide additional protection against coronary heart disease, colon cancer, and skin irritation1.
   • 480 mg per day: Further research is needed to fully understand the effects at this level.
   • 960 mg per day: Similarly, more studies are required to determine the impact of this higher dose1.

2. Two Doses Per Day:

   • 30 mg twice daily: Consistent intake of avenanthramides may enhance their benefits.
   • 60 mg twice daily: This regimen could potentially amplify the anti-inflammatory and antioxidant effects.
   • 120 mg twice daily: Avenanthramides might exert stronger antiproliferative activity.
   • 240 mg twice daily: Research is ongoing to assess the impact of this dosage.
   • 480 mg twice daily: As with higher single doses, more evidence is needed.
   • 960 mg twice daily: At this level, avenanthramides warrant further investigation1.

Keep in mind that these findings are based on existing research, and individual responses may vary. If you’re considering avenanthramide supplementation, consult with a healthcare professional to determine the most appropriate dosage for your specific needs.

[prophetoffactz]

"The safety and bioavailability study will evaluate avenanthramides as a stand-alone therapy or potentially in combination with carriers recently developed using our PGX technology to address some inflammation-based diseases, which we believe shows great promise.” Aug. 4, 2020 We've never seen promising data combining CZO's avenanthramide with a newer generation PGX carrier. That'

[prophetoffactz]

We've never seen preclinical data for the avenanthramide pill or in combination with a newer generation PGX carrier. That shows how much hidden value there could be in this program.